
Outlook Therapeutics OTLK
$ 0.64
2.7%
Outlook Therapeutics EBITDA per Share | OTLK
Annual EBITDA per Share Outlook Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.92 | -3.86 | -4.24 | -0.3 | -0.34 | -0.493 | -1.19 | -5.39 | -11.1 | -22.9 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.3 | -22.9 | -5.17 |
Quarterly EBITDA per Share Outlook Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.43 | -0.17 | -0.22 | -0.22 | - | - | - | -0.89 | - | - | - | -0.79 | - | - | - | -0.07 | -0.22 | -0.08 | -0.09 | -0.07 | -0.26 | -0.07 | -0.08 | -0.12 | -0.47 | -0.13 | -0.29 | -0.27 | -1.43 | -0.21 | -0.25 | -0.96 | -4.22 | -0.19 | -0.37 | -0.1 | -1.3 | -0.27 | -0.11 | -0.74 | -2.58 | -1.14 | -1.22 | -1.21 | -3 | -1.11 | -1.47 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.07 | -4.22 | -0.706 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Фармсинтез
LIFE
|
-0.23 | - | - | - | ||
|
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | ||
|
Amryt Pharma plc
AMYT
|
-0.16 | - | - | $ 621 M | ||
|
ASLAN Pharmaceuticals Limited
ASLN
|
-0.09 | - | -14.27 % | $ 1.7 M | ||
|
Revolution Medicines
RVMD
|
-6.18 | $ 207.32 | 0.24 % | $ 39.4 B | ||
|
Rhythm Pharmaceuticals
RYTM
|
-2.95 | $ 101.8 | 0.08 % | $ 6.62 B | ||
|
Rezolute
RZLT
|
-1.05 | $ 4.4 | 0.88 % | $ 334 M | ||
|
Sana Biotechnology
SANA
|
-0.94 | $ 3.45 | 0.77 % | $ 874 M | ||
|
Seer
SEER
|
-1.54 | $ 1.95 | 0.26 % | $ 108 M | ||
|
Precigen
PGEN
|
-0.34 | $ 6.87 | 0.14 % | $ 2.15 B | ||
|
SIGA Technologies
SIGA
|
0.34 | $ 3.2 | 1.86 % | $ 229 M | ||
|
Syndax Pharmaceuticals
SNDX
|
-3.08 | $ 19.94 | 0.05 % | $ 1.73 B | ||
|
Soligenix
SNGX
|
-2.28 | $ 0.38 | 1.18 % | $ 1.97 M | ||
|
Spruce Biosciences
SPRB
|
-47.6 | $ 59.09 | 2.0 % | $ 45.3 M | ||
|
Sarepta Therapeutics
SRPT
|
-6.54 | $ 20.94 | 0.04 % | $ 2.1 B | ||
|
Stoke Therapeutics
STOK
|
-0.32 | $ 30.05 | 0.81 % | $ 1.78 B | ||
|
Sutro Biopharma
STRO
|
-17.8 | $ 19.1 | 0.34 % | $ 162 M | ||
|
Shattuck Labs
STTK
|
-0.69 | $ 6.5 | 0.29 % | $ 452 M | ||
|
Supernus Pharmaceuticals
SUPN
|
0.52 | $ 42.43 | 0.23 % | $ 2.4 B | ||
|
Savara
SVRA
|
-0.56 | $ 5.53 | 2.98 % | $ 1.23 B | ||
|
China SXT Pharmaceuticals
SXTC
|
-10.4 | $ 2.24 | 0.45 % | $ 1.52 M | ||
|
Takeda Pharmaceutical Company Limited
TAK
|
217 | $ 18.32 | 1.49 % | $ 28.9 B | ||
|
Bio-Techne Corporation
TECH
|
2.24 | $ 72.31 | 0.01 % | $ 11.3 B | ||
|
Tenax Therapeutics
TENX
|
-1.44 | $ 1.98 | 2.06 % | $ 77.7 M | ||
|
Teva Pharmaceutical Industries Limited
TEVA
|
2.76 | $ 36.76 | 1.21 % | $ 42.1 B | ||
|
TG Therapeutics
TGTX
|
0.85 | $ 55.74 | 0.58 % | $ 8.04 B | ||
|
Trevi Therapeutics
TRVI
|
-0.37 | $ 16.82 | 1.17 % | $ 2.27 B | ||
|
Taysha Gene Therapies
TSHA
|
-0.34 | $ 5.48 | 0.54 % | $ 1.75 B | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
-2.67 | $ 69.37 | 0.35 % | $ 193 M | ||
|
UroGen Pharma Ltd.
URGN
|
-2.59 | $ 43.82 | 0.02 % | $ 2.11 B | ||
|
United Therapeutics Corporation
UTHR
|
35.6 | $ 497.97 | 2.12 % | $ 22.1 B | ||
|
Spero Therapeutics
SPRO
|
0.11 | $ 1.19 | 0.41 % | $ 66.7 M | ||
|
Scholar Rock Holding Corporation
SRRK
|
-3.34 | $ 57.42 | 3.78 % | $ 6.59 B | ||
|
Jounce Therapeutics
JNCE
|
-0.97 | - | - | $ 98.4 M | ||
|
NextCure
NXTC
|
-19.5 | $ 8.42 | 7.67 % | $ 23.9 M | ||
|
Verrica Pharmaceuticals
VRCA
|
-1.13 | $ 5.26 | 0.75 % | $ 56 M | ||
|
Viridian Therapeutics
VRDN
|
-3.56 | $ 23.17 | 1.09 % | $ 2.36 B | ||
|
Zosano Pharma Corporation
ZSAN
|
-0.27 | - | 7.23 % | $ 2.72 M | ||
|
Vertex Pharmaceuticals Incorporated
VRTX
|
17.1 | $ 528.9 | 0.22 % | $ 135 B | ||
|
Verastem
VSTM
|
-2.45 | $ 8.08 | 0.55 % | $ 560 M | ||
|
vTv Therapeutics
VTVT
|
-0.688 | $ 32.79 | 0.03 % | $ 130 M | ||
|
Voyager Therapeutics
VYGR
|
-2.18 | $ 3.4 | 3.85 % | $ 200 M | ||
|
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | ||
|
Wave Life Sciences Ltd.
WVE
|
-1.26 | $ 4.91 | 1.03 % | $ 828 M | ||
|
Tonix Pharmaceuticals Holding Corp.
TNXP
|
-14.5 | $ 13.16 | 0.15 % | $ 112 M | ||
|
Xenetic Biosciences
XBIO
|
-1.67 | $ 4.28 | 0.86 % | $ 7.28 M | ||
|
XBiotech
XBIT
|
-1.77 | $ 2.18 | 0.23 % | $ 66.5 M | ||
|
Exicure
XCUR
|
-0.63 | $ 1.41 | 12.8 % | $ 8.88 M | ||
|
Xenon Pharmaceuticals
XENE
|
-4.68 | $ 59.55 | 0.18 % | $ 4.72 B | ||
|
Xeris Pharmaceuticals
XERS
|
0.16 | $ 8.48 | 0.12 % | $ 1.36 B |